INFI News and Press, Infinity Pharmaceuticals Inc. From 05/03/22

Infinity Pharmaceuticals press release (NASDAQ:INFI): Q1 GAAP EPS of -$0.14 in-line. Revenue of $0.65M (+38.3% Y/Y) beats by $0.39M. 2022 Guidance: Net Loss: Infinity expects net loss for 2022 to range from $45 million to $55 million. Cash and Investments: Infinity expects to end 2022 wi...

– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer (TNBC) expected to initiate by year-end 2022 – – MARIO-P, a clinical program designed to expand eganelisib development in additional solid t...

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, May 3rd, 2022, at 4:30 pm ET to report its financial res...

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, granted non-statutory stock options to two new employees on April 6, 2022. The grant...

Shares of Infinity Pharmaceuticals (INFI +26.6%) rose after reporting better-than-expected FY revenue from royalties. FY21 royalty revenue grew +8.09% Y/Y to ~$1.86M. FY net loss widened to -$45.3M, compared to -$40.5M a year ago. Research and development expenses increased to $31.65M,  ...

Infinity Pharmaceuticals, Inc. (INFI) Q4 2021 Earnings Conference Call March 29, 2022 4:30 PM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman & CEO Robert Ilaria, Jr - Chief Medical Officer Larry Bloch - President & Treasurer Conference...

Infinity Pharmaceuticals press release (NASDAQ:INFI): FY GAAP EPS of -$0.53 in-line. Revenue of $1.86M (+8.8% Y/Y) beats by $0.16M. Total cash, cash equivalents and available-for-sale securities of $80.7 million, compared to $34.1 million at December 31, 2020. Outlook 2022: Net Loss: Inf...

– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer expected to initiate by the end of 2022 – – MARIO-P, a study designed to expand eganelisib development in additional solid tumor indications...

Infinity Pharmaceuticals (NASDAQ:INFI) is scheduled to announce Q4 earnings results on Tuesday, March 29th, after market close. The consensus EPS Estimate is -$0.14 (+79.4% Y/Y) and the consensus Revenue Estimate is $0.29M (-83.1% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward...

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, March 29 th , 2022 at 4:30 p.m. ET to report its fin...